Tirdzniecība First Wave BioPharma, Inc. - FWBI CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Tirdzniecības Nosacījumi
| Starpība | 0.0802 | ||||||||
|
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.024068% | ||||||||
|
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | 0.001846% | ||||||||
| Nakts laika nodeva | 21:00 (UTC) | ||||||||
| Min. tirgotais daudzums | 0.001 | ||||||||
| Valūta | USD | ||||||||
| Drošības rezerve | 20% | ||||||||
| Fondu birža | United States of America | ||||||||
| Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Galvenie Statistikas Dati
| Iepriekš. aizvērt* | 2.9994 |
| Atvērt* | 2.9691 |
| Izmaiņas par 1 gadu* | 172.39% |
| Dienas Diapazons* | 2.87 - 2.9797 |
| 52 ned Diapazons | 2.76-289.80 |
| Vidējais apjoms (10 dienas) | 46.20K |
| Vidējais apjoms (3 mēneši) | 11.17M |
| Tirgus Kapitalizācija | 4.70M |
| Cenas/Peļņas Attiecība | -100.00K |
| Izvietotās Akcijas | 1.55M |
| Ieņēmumi | N/A |
| EPS | -248.68 |
| Dividende (Ienesīgums %) | N/A |
| Beta | 1.69 |
| Nākamās Peļņas Datums | N/A |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
|---|---|---|---|---|---|---|
| Mar 24, 2023 | 2.9994 | 0.0199 | 0.67% | 2.9795 | 3.0290 | 2.9692 |
| Mar 23, 2023 | 3.0092 | -0.0587 | -1.91% | 3.0679 | 3.1978 | 2.9791 |
| Mar 22, 2023 | 3.0193 | -0.0990 | -3.17% | 3.1183 | 3.1774 | 2.9687 |
| Mar 21, 2023 | 3.1678 | 0.0892 | 2.90% | 3.0786 | 3.1678 | 3.0582 |
| Mar 20, 2023 | 3.0588 | 0.0499 | 1.66% | 3.0089 | 3.1283 | 2.9691 |
| Mar 17, 2023 | 3.0291 | 0.0600 | 2.02% | 2.9691 | 3.0391 | 2.9591 |
| Mar 16, 2023 | 2.9695 | 0.1986 | 7.17% | 2.7709 | 3.0093 | 2.7704 |
| Mar 15, 2023 | 2.9302 | 0.1883 | 6.87% | 2.7419 | 2.9302 | 2.6917 |
| Mar 14, 2023 | 2.7715 | -0.1685 | -5.73% | 2.9400 | 2.9400 | 2.6912 |
| Mar 13, 2023 | 3.0191 | -0.5440 | -15.27% | 3.5631 | 3.5731 | 2.9982 |
| Mar 10, 2023 | 3.6238 | 0.0103 | 0.29% | 3.6135 | 3.6634 | 3.5640 |
| Mar 9, 2023 | 3.7131 | -0.2472 | -6.24% | 3.9603 | 4.1786 | 3.5639 |
| Mar 8, 2023 | 3.5246 | -0.0395 | -1.11% | 3.5641 | 3.6041 | 3.4648 |
| Mar 7, 2023 | 3.5148 | -0.0593 | -1.66% | 3.5741 | 3.7130 | 3.5047 |
| Mar 6, 2023 | 3.6437 | 0.0800 | 2.24% | 3.5637 | 3.7130 | 3.5637 |
| Mar 3, 2023 | 3.6436 | 0.1790 | 5.17% | 3.4646 | 3.7723 | 3.4646 |
| Mar 2, 2023 | 3.5146 | 0.0496 | 1.43% | 3.4650 | 3.5546 | 3.4650 |
| Mar 1, 2023 | 3.5346 | 0.0200 | 0.57% | 3.5146 | 3.5645 | 3.4650 |
| Feb 28, 2023 | 3.4750 | 0.1891 | 5.75% | 3.2859 | 3.5248 | 3.2856 |
| Feb 27, 2023 | 3.4157 | -0.2371 | -6.49% | 3.6528 | 3.7229 | 3.3658 |
First Wave BioPharma, Inc. Events
| Laiks (UTC) (UTC) | Valsts | Notikums |
|---|---|---|
| No events scheduled | ||
- Ikgadējs
- Ceturkšņa
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 0 | 0 | 0 | 0 | 0 |
| Kopējie Darbības Izdevumi | 59.0569 | 26.8313 | 14.7437 | 13.4318 | 10.2212 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 18.3696 | 7.27976 | 6.04227 | 8.17431 | 6.93171 |
| Pētniecība un Attīstība | 38.3204 | 19.105 | 7.85849 | 4.98555 | 2.39548 |
| Depreciation / Amortization | 0.015 | 0.048 | 0.84299 | 0.06191 | 0.754 |
| Other Operating Expenses, Total | 0 | 0.21 | 0.14 | ||
| Darbības Izdevumi | -59.0569 | -26.8313 | -14.7437 | -13.4318 | -10.2212 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -0.01007 | -5.84013 | -0.43394 | -0.10185 | -0.8752 |
| Citi, Neto | 0.5291 | 0 | |||
| Neto Ienākumi Pirms Nodokļu Nomaksas | -58.5378 | -32.6715 | -15.1777 | -13.5336 | -11.0964 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -58.5378 | -32.6715 | -15.1777 | -13.5336 | -11.0964 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -58.5378 | -32.6715 | -15.1777 | -13.5336 | -11.0964 |
| Neto Ienākumi | -58.5378 | -32.6715 | -15.1777 | -13.5336 | -11.0964 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -84.5186 | -41.7323 | -15.1777 | -13.5336 | -11.0964 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -84.5186 | -41.7323 | -15.1777 | -13.5336 | -11.0964 |
| Atšķaidītie Neto Ienākumi | -84.5186 | -41.7323 | -15.1777 | -13.5336 | -11.0964 |
| Atšķaidītie Ienākumi par Akcijām | 0.0425 | 0.01354 | 0.01068 | 0.00735 | 0.00506 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -1988.67 | -3082.15 | -1421.4 | -1840.94 | -2192.55 |
| Atšķaidītā Normalizētā Peļņa par Akciju | -1933.33 | -3052.71 | -1421.4 | -1840.94 | -2192.55 |
| Ienākumi | 0 | ||||
| Neparedzēti Izdevumi (Ienākumi) | 2.35199 | 0.39857 | |||
| Total Adjustments to Net Income | -25.9807 | -9.06087 |
| Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 0 | 0 | 0 | 0 | 0 |
| Kopējie Darbības Izdevumi | -4.38953 | 14.7879 | 9.38207 | 11.167 | 30.3995 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 2.90445 | 6.90451 | 4.40556 | 3.03678 | 6.02116 |
| Pētniecība un Attīstība | 0.79107 | 7.88341 | 4.97652 | 5.77821 | 24.3783 |
| Depreciation / Amortization | |||||
| Darbības Izdevumi | 4.38953 | -14.7879 | -9.38207 | -11.167 | -30.3995 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | 0.0018 | -0.00775 | -0.00547 | -0.00123 | -0.00074 |
| Citi, Neto | 0 | -0.2393 | -0.2393 | -0.00428 | -0.00057 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | 4.39133 | -15.035 | -9.62684 | -11.1725 | -30.4008 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | 4.39133 | -15.035 | -9.62684 | -11.1725 | -30.4008 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | 4.39133 | -15.035 | -9.62684 | -11.1725 | -30.4008 |
| Neto Ienākumi | 4.39133 | -15.035 | -9.62684 | -11.1725 | -30.4008 |
| Total Adjustments to Net Income | -0.15758 | -0.18792 | -0.09079 | -0.11623 | -0.11809 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | 4.23375 | -15.2229 | -9.71763 | -11.2887 | -30.5189 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | 4.23375 | -15.2229 | -9.71763 | -11.2887 | -30.5189 |
| Atšķaidītie Neto Ienākumi | 4.23375 | -15.2229 | -9.71763 | -11.2887 | -30.5189 |
| Atšķaidītie Ienākumi par Akcijām | 0.23225 | 0.18244 | 0.09642 | 0.06153 | 9.34236 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | 18.2291 | -83.4388 | -100.782 | -183.468 | -3.26672 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Atšķaidītā Normalizētā Peļņa par Akciju | 18.2291 | -83.4388 | -100.782 | -145.242 | -3.26672 |
| Neparedzēti Izdevumi (Ienākumi) | 2.35199 | ||||
| Other Operating Expenses, Total | -8.08505 | 0 |
- Ikgadējs
- Ceturkšņa
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 9.42495 | 7.86978 | 3.40829 | 4.8 | 1.95257 |
| Nauda un Īstermiņa Ieguldījumi | 8.24868 | 6.06214 | 0.1758 | 1.11434 | 0.57347 |
| Cash | 8.24868 | 6.06214 | 0.1758 | 1.11434 | 0.57347 |
| Īstermiņa Ieguldījumi | |||||
| Debitoru Parādu Kopsumma, Neto | 0 | 0.55149 | 2.6373 | 3.17268 | 1.10413 |
| Prepaid Expenses | 1.17627 | 1.25615 | 0.59519 | 0.51298 | 0.27496 |
| Total Assets | 11.79 | 12.9239 | 8.90288 | 7.4694 | 5.47967 |
| Property/Plant/Equipment, Total - Net | 0.40931 | 0.09257 | 0.15978 | 0.12885 | 0.13399 |
| Goodwill, Net | 1.91171 | 2.05405 | 1.88669 | 1.92483 | 2.01624 |
| Intangibles, Net | 0 | 2.87954 | 3.40708 | 0.57048 | 1.34596 |
| Other Long Term Assets, Total | 0.04401 | 0.02792 | 0.04105 | 0.04523 | 0.03092 |
| Total Current Liabilities | 12.3004 | 15.5454 | 4.28564 | 2.99552 | 2.47908 |
| Payable/Accrued | 0 | 0.53343 | 0.6701 | 2.05534 | |
| Accrued Expenses | 0.49706 | 0.18443 | 0.15441 | 0.53829 | 0.00719 |
| Notes Payable/Short Term Debt | 0.64124 | 0.55241 | 1.5213 | 0.25503 | 0.41655 |
| Other Current Liabilities, Total | 8.48018 | 13.25 | 0.39299 | ||
| Total Liabilities | 19.6115 | 15.5646 | 4.28564 | 2.99552 | 3.81908 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 7.31114 | 0.01912 | 0 | 0 | 1.34 |
| Total Equity | -7.82155 | -2.64069 | 4.61724 | 4.47387 | 1.66059 |
| Common Stock | 0.00149 | 0.00312 | 0.00268 | 0.00177 | 0.00121 |
| Additional Paid-In Capital | 147.305 | 93.8349 | 68.5759 | 53.1393 | 37.6696 |
| Retained Earnings (Accumulated Deficit) | -153.904 | -95.3662 | -62.6947 | -47.5171 | -33.9834 |
| Other Equity, Total | -1.22414 | -1.11255 | -1.26656 | -1.15011 | -2.02679 |
| Total Liabilities & Shareholders’ Equity | 11.79 | 12.9239 | 8.90288 | 7.4694 | 5.47967 |
| Total Common Shares Outstanding | 14.8559 | 3.11503 | 2.68005 | 1.77049 | 1.20426 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Property/Plant/Equipment, Total - Gross | 0.42402 | 0.13097 | 0.4233 | 0.33225 | |
| Accumulated Depreciation, Total | -0.01471 | -0.0384 | -0.26352 | -0.20339 | |
| Accounts Payable | 2.68191 | 1.55859 | 1.68351 | 1.53211 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 6.55017 | 9.42495 | 7.50249 | 8.61528 | 13.1704 |
| Nauda un Īstermiņa Ieguldījumi | 5.69499 | 8.24868 | 7.21065 | 8.07449 | 12.0256 |
| Cash | 5.69499 | 8.24868 | 7.21065 | 8.07449 | 12.0256 |
| Debitoru Parādu Kopsumma, Neto | 0.02806 | 0 | 0 | 0 | 0.50166 |
| Prepaid Expenses | 0.82713 | 1.17627 | 0.29184 | 0.54079 | 0.64313 |
| Total Assets | 8.82544 | 11.79 | 12.424 | 13.7768 | 17.9829 |
| Property/Plant/Equipment, Total - Net | 0.3788 | 0.40931 | 0.44889 | 0.48488 | 0.06162 |
| Property/Plant/Equipment, Total - Gross | 0.40083 | 0.42402 | 0.45632 | 0.4861 | 0.0812 |
| Accumulated Depreciation, Total | -0.02203 | -0.01471 | -0.00743 | -0.00123 | -0.01958 |
| Goodwill, Net | 1.86207 | 1.91171 | 1.94474 | 1.99129 | 1.97396 |
| Intangibles, Net | 0 | 2.48388 | 2.61576 | 2.74765 | |
| Other Long Term Assets, Total | 0.0344 | 0.04401 | 0.04403 | 0.0696 | 0.02924 |
| Total Current Liabilities | 14.2157 | 12.3004 | 19.0983 | 6.45412 | 3.57464 |
| Accounts Payable | 3.44993 | 2.68191 | 18.4478 | 4.44991 | 1.44072 |
| Accrued Expenses | 0.7883 | 0.49706 | 0.22987 | 0.31246 | 0.32383 |
| Notes Payable/Short Term Debt | 0.40277 | 0.64124 | 0 | 0.13957 | 0.34708 |
| Other Current Liabilities, Total | 9.57473 | 8.48018 | 0.42063 | 1.55218 | 1.46302 |
| Total Liabilities | 18.0652 | 19.6115 | 19.394 | 6.73988 | 3.58121 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 3.8495 | 7.31114 | 0.29569 | 0.28575 | 0.00657 |
| Total Equity | -9.23979 | -7.82155 | -6.96999 | 7.03692 | 14.4017 |
| Common Stock | 0.00215 | 0.00149 | 0.00111 | 0.00826 | 0.00749 |
| Additional Paid-In Capital | 155.571 | 147.305 | 137.028 | 120.585 | 118.693 |
| Retained Earnings (Accumulated Deficit) | -163.531 | -153.904 | -142.732 | -112.331 | -103.052 |
| Other Equity, Total | -1.28254 | -1.22414 | -1.26711 | -1.2255 | -1.24734 |
| Total Liabilities & Shareholders’ Equity | 8.82544 | 11.79 | 12.424 | 13.7768 | 17.9829 |
| Total Common Shares Outstanding | 21.5488 | 14.8559 | 11.1152 | 8.25851 | 7.49269 |
| Preferred Stock - Non Redeemable, Net | 0 |
- Ikgadējs
- Ceturkšņa
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Neto ienākumi/Sākuma Līnija | -58.5378 | -32.6715 | -15.1777 | -13.5336 | -11.0964 |
| Nauda no Darbības | -32.2882 | -11.2215 | -14.0335 | -10.8693 | -7.18464 |
| Nauda no Darbības | 0.01471 | 0.0378 | 0.0631 | 0.06191 | 0.04952 |
| Amortization | 0.52755 | 0.52755 | 0.95695 | 0.73654 | 0.70448 |
| Bezskaidras Naudas Preces | 8.60641 | 6.73365 | 1.82513 | 3.57765 | 3.42595 |
| Izmaiņas Apgrozāmajā Kapitālā | 17.101 | 14.1509 | -1.70099 | -1.7118 | -0.26821 |
| Nauda no Ieguldījumu Darbībām | -10.3195 | 0.08735 | -0.0241 | -0.30547 | -0.03217 |
| Kapitālie Izdevumi | -0.06949 | -0.00417 | -0.0241 | -0.30547 | -0.03217 |
| Nauda no Darbībām ar Finansēšanu | 44.7635 | 17.0461 | 13.145 | 11.7121 | 6.01322 |
| Naudas Plūsma Finansēšanas Posteņos | 0 | ||||
| Akciju Izsniegšana (Atkāpšanās), Neto | 44.6747 | 14.1861 | 9.53834 | 11.9028 | 5.00923 |
| Parādu Izsniegšana (Atkāpšanās), Neto | 0.08883 | 2.86003 | 3.60664 | -0.19068 | 1.00399 |
| Ārvalstu Valūtas Ietekme | 0.03076 | -0.02559 | -0.02593 | 0.00354 | 0.00353 |
| Neto Izmaiņas Naudā | 2.18654 | 5.88635 | -0.93855 | 0.54087 | -1.20005 |
| Cash Taxes Paid | 0 | 0 | 0 | 0 | |
| Samaksātie Procenti Naudā | 0 | 0.10546 | 0.00803 | 0.00401 | 0.00415 |
| Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | -10.25 | 0.09152 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -9.62684 | -58.5378 | -47.3654 | -16.9646 | -7.68563 |
| Cash From Operating Activities | -7.91207 | -32.2882 | -26.4254 | -10.6961 | -5.07339 |
| Cash From Operating Activities | 0.00732 | 0.01471 | 0.00939 | 0.00301 | 0.00102 |
| Amortization | 0 | 0.52755 | 0.39566 | 0.26377 | 0.13189 |
| Non-Cash Items | 0.36042 | 8.60641 | 2.04186 | 1.7359 | 1.80638 |
| Cash Interest Paid | 0 | 0 | 0 | 0 | 0.00514 |
| Changes in Working Capital | 1.34703 | 17.101 | 18.493 | 4.26576 | 0.67294 |
| Cash From Investing Activities | -10.3195 | -10.3215 | -9.07393 | 0 | |
| Capital Expenditures | -0.06949 | -0.07145 | -0.07393 | 0 | |
| Cash From Financing Activities | 5.36715 | 44.7635 | 37.9406 | 21.8326 | 11.0506 |
| Financing Cash Flow Items | -2.41496 | -9.53235 | |||
| Issuance (Retirement) of Stock, Net | 8.02057 | 44.6747 | 38.493 | 22.2454 | 20.7883 |
| Issuance (Retirement) of Debt, Net | -0.23847 | 0.08883 | -0.55241 | -0.41284 | -0.20532 |
| Foreign Exchange Effects | -0.00877 | 0.03076 | -0.04525 | -0.05019 | -0.01374 |
| Net Change in Cash | -2.5537 | 2.18654 | 1.1485 | 2.01235 | 5.96349 |
| Cash Taxes Paid | 0 | 0 | 0 | ||
| Other Investing Cash Flow Items, Total | -10.25 | -10.25 | -9 |
| Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
|---|---|---|---|---|---|---|
| Armistice Capital LLC | Hedge Fund | 2.7101 | 41995 | 41995 | 2022-12-31 | HIGH |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.7614 | 11799 | 0 | 2022-12-31 | LOW |
| Sapirstein (James E) | Individual Investor | 0.6914 | 10714 | -32143 | 2023-03-16 | HIGH |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.4632 | 7178 | 7178 | 2022-12-31 | MED |
| Romano (Sarah M.) | Individual Investor | 0.3457 | 5357 | -16072 | 2023-03-16 | MED |
| Hoffman (David Andrew) | Individual Investor | 0.2509 | 3888 | -9080 | 2023-03-16 | HIGH |
| Borkowski (Edward J) | Individual Investor | 0.2083 | 3228 | -9080 | 2023-03-16 | LOW |
| Riddell (Alastair) | Individual Investor | 0.1993 | 3089 | -9080 | 2023-03-16 | HIGH |
| Casamento (Charles J) | Individual Investor | 0.1989 | 3082 | -9080 | 2023-03-16 | LOW |
| Coelho (Mary Theresa) | Individual Investor | 0.1953 | 3027 | -9079 | 2023-03-16 | LOW |
| Susquehanna International Group, LLP | Investment Advisor | 0.1408 | 2182 | 2182 | 2022-12-31 | MED |
| UBS Financial Services, Inc. | Investment Advisor | 0.1315 | 2038 | 1752 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.0987 | 1529 | 1529 | 2022-12-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 0.063 | 977 | 0 | 2023-02-28 | LOW |
| Tower Research Capital LLC | Hedge Fund | 0.0626 | 970 | 497 | 2022-12-31 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.0243 | 377 | 0 | 2022-12-31 | LOW |
| Advisor Group, Inc | Investment Advisor | 0.0185 | 286 | 286 | 2022-12-31 | LOW |
| Wells Fargo Advisors | Research Firm | 0.0017 | 27 | 0 | 2022-12-31 | LOW |
| U.S. Bancorp Asset Management, Inc. | Investment Advisor | 0.0015 | 24 | 0 | 2022-12-31 | LOW |
| BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.0014 | 22 | 0 | 2022-12-31 | LOW |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group500K+
Tirgotāji
92K+
Ikmēneša aktīvie klienti
$53M+
Ikmēneša ieguldījumu apjoms
$30M+
Izņemts katru mēnesi
Treidinga kalkulators
Aprēķiniet iespējamo peļņu un zaudējumus, uzsākot CFD darījumu noteiktā dienā (izvēlaties datumu) un slēdzot darījumu citā dienā (izvēlaties datumu).
Tirdzniecības komisija
0
- 1:1
Finanšu svira
1:1
- 20
- 100
- 500
- 1000
- 10000
Investīcija
Darījuma apjoms (Kredītplecs x Investīcija):
Atvēršana
Aizvēršana
Īss Garšs
First Wave BioPharma, Inc. Company profile
Par First Wave BioPharma, Inc.
First Wave BioPharma, Inc., agrāk AzurRx BioPharma, Inc., ir klīniskās stadijas biofarmācijas uzņēmums. Tas nodarbojas ar mērķtiecīgu, nesistēmisku terapiju izstrādi kuņģa un zarnu trakta slimību ārstēšanai. Uzņēmums koncentrējas uz to, lai attīstītu terapeitisko izstrādi, kas balstīta uz divām tehnoloģijām: niklosamīdu, iekšķīgi lietojamu mazu molekulu ar pretvīrusu un pretiekaisuma īpašībām, un bioloģisko adrulipāzi, rekombinantu lipāzes fermentu, kas paredzēts tauku un citu uzturvielu sagremošanai. Uzņēmuma niklosamīda portfeli veido trīs klīniskās programmas: FW-COV - COVID-19 kuņģa un zarnu trakta infekciju ārstēšanai; FW-UP - čūlainā proktīta (UP) un čūlainā proktosigmoidīta ārstēšanai; un FW-ICI-AC - 1. un 2. pakāpes imunitātes kontrolpunkta inhibitoru izraisīta kolīta un caurejas ārstēšanai onkoloģiskiem pacientiem. Uzņēmums attīsta arī FW-EPI (adrulipāzi) eksokrīnās aizkuņģa dziedzera mazspējas (EPI) ārstēšanai pacientiem ar cistisko fibrozi un hronisku pankreatītu.
| Industry: | Biotechnology & Medical Research (NEC) |
777 Yamato Road
Suite 502
33431
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 500 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com